Hepatitis Clinical Trial
Official title:
A Double-Blind, Randomized, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Pioglitazone in Patients With Nonalcoholic Steatohepatitis
NCT number | NCT01068444 |
Other study ID # | KMUH-HB9608 |
Secondary ID | |
Status | Completed |
Phase | Phase 2 |
First received | |
Last updated | |
Start date | April 2009 |
Est. completion date | July 2020 |
Verified date | July 2020 |
Source | Kaohsiung Medical University Chung-Ho Memorial Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Recent studies have demonstrated that PPARγ as well as diet control could improve glycemic
control, decrease serum ALT level, decrease hepatic fat distribution, and increase
intrahepatic insulin sensitivity. The purposes of this study are:
1. Primary aims:
1. Comparison between Pioglitazone and placebo groups in terms of steatosis and liver
function tests.
2. Evaluation of clinical safety of Pioglitazone
2. Secondary aims:
1. Comparison between Pioglitazone and placebo groups in terms of liver necroinflammation
and fibrosis.
2. The impact of Pioglitazone on the related metabolic index, including insulin
resistance(HOMA-IR), newly-onset diabetes, metabolic syndrome, lipid profiles (T-Chol,
HDL-C, LDL-C, TG).
3. Comparison between Pioglitazone and placebo groups in terms of high-sensitive C-reactive
protein changes.
3. Interventional aim: Assessment the association between magnetic resonance imaging study
and intrahepatic fat distribution before and after Pioglitazone treatment.
Status | Completed |
Enrollment | 90 |
Est. completion date | July 2020 |
Est. primary completion date | July 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility |
Main inclusion criteria: 1. Male and female patients with 18-70 years of age 2. Liver biopsy findings consistent with the diagnosis of NASH with or without compensated cirrhosis within one year before baseline 3. Compensated liver disease 4. Negative urine or blood pregnancy test (for women of childbearing potential) documented within the 24-hour period prior to the first dose of study drug 5. All fertile males and females must be using two forms of effective contraception during treatment during the 3 months after treatment. 6. ALT level between 1.3-5 x ULN for 2 occasions during 6 months before screening. 7. HbA1C ? 8.0 during screening Main exclusion criteria: 1. Therapy with any systemic anti-neoplastic or immunomodulatory treatment (including supraphysiologic doses of steroids and radiation) *6 months before baseline. 2. History or other evidence of a medical condition associated with chronic liver disease other than NASH (e.g., hemochromatosis, autoimmune hepatitis, alcoholic liver disease, > 20 g/day for female or > 40 g/day for male, toxin exposures) 3. hepatocellular carcinoma 4. History or other evidence of bleeding from esophageal varices or other conditions consistent with decompensated liver disease 5. Serum creatinine level >1.5 times the upper limit of normal at screening and calculated creatinine clearance as calculated by Cockcroft and Gault < 60mL/min during screening 6. History of ischemic heart disease during screening 7. New York Heart Association (NYHA) Functional Class 1-4 cardiac status during screening 8. Albumin <3.2g/dL during screening 9. Total bilirubin >1.2 x ULN during screening. Patients with history of asymptomatic indirect hyperbilirubinemia whose total bilirubin < 2 x ULN and direct bilirubin < 20% of total bilirubin could be included. 10. History of prothrombin time > 15 seconds or International normalized ratio (INR) > 1.3 11. Organ, stem cell, or bone marrow transplant 12. History of serious concurrent medical illness that in the investigator's opinion might interfere with therapy this includes significant systemic illnesses (other than liver disease) such as chronic pancreatitis 13. Active systemic autoimmune disorder 14. Pregnancy (or lactation) or, in subjects capable of bearing children, inability / unwillingness to practice adequate contraception 15. Females of child-bearing potential (post-puberty) unwilling or unable to have pregnancy testing at any study visit 16. Therapy with a systemic antiviral agent (with the exception of prophylaxis or treatment of influenza or chronic HSV) within the past 30 days prior to screening. 17. Concurrent participation in another clinical trial in which the subject is or will be exposed to another investigational or a non-investigational drug or device within 6 weeks of the screening visit 18. Current therapy with insulin within 1 week prior to screening. 19. Experienced use with PPARg agonist (e.g., rosiglitazone, pioglitazone) within 6 months prior to screening. 20. Known hypersensitivity to any component of PPARg agonists 21. A history of hepatotoxicity to TZDs and/or a history of severe edema or a medically serious fluid-related event associated with the use of TZDs 22. History of metformin use within 3 months prior to screening. 23. Type ? diabetes 24. Seropositive of HBsAg, anti-HCV or anti-HIV during screening or 3 month prior to screening. |
Country | Name | City | State |
---|---|---|---|
Taiwan | Kaohsiung Medical University Hospital | Kaohsiung | |
Taiwan | Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung Medical University | Kaohsiung City |
Lead Sponsor | Collaborator |
---|---|
Kaohsiung Medical University Chung-Ho Memorial Hospital |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Comparison between Pioglitazone and placebo groups in terms of steatosis and liver function tests | 9 months | ||
Primary | Evaluation of clinical safety of Pioglitazone | 9 months | ||
Secondary | Comparison between Pioglitazone and placebo groups in terms of liver necroinflammation and fibrosis. | 9 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05738681 -
Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial
|
Phase 2/Phase 3 | |
Recruiting |
NCT05989958 -
The Safety and Tolerability Study of HepaCure in Chinese Subjects With Acute-On-Chronic Liver Failure
|
Phase 1 | |
Not yet recruiting |
NCT06395129 -
Low Dead-space Injecting Equipment Distribution Program for People Who Inject Drugs in Low- and Middle-income Countries
|
||
Terminated |
NCT01443923 -
Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV
|
Phase 4 | |
Completed |
NCT00679692 -
Evaluation the Growth Factors(IGF-1,IGFBP-3and HGH)in Patients With Chronic Liver Disease
|
N/A | |
Completed |
NCT00300209 -
Manhattan HIV/Hepatology Brain Bank
|
N/A | |
Recruiting |
NCT05563961 -
A Partial Randomized, Single-blind or Open-label, Dose-escalation With Multiple-dose Design Study to Evaluate the Pharmacokinetics of Acetaminophen and Its Toxic Metabolites With Panadol® and SafeTynadol® in Healthy Volunteers
|
N/A | |
Recruiting |
NCT05635266 -
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
|
||
Completed |
NCT00160407 -
Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH)
|
Phase 4 | |
Recruiting |
NCT03692897 -
An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection
|
||
Completed |
NCT03509688 -
The Curative Effect of Entecavir Combined Resveratrol on HBV patients-a Multi-center, Random, Open Clinical Trial
|
N/A | |
Recruiting |
NCT02275195 -
Immune Cell Dysfunction in Severe Alcoholic Hepatitis
|
||
Completed |
NCT01740089 -
Algeron (Cepeginterferon Alfa-2b) Compared With PegIntron (Peginterferon Alfa-2b) for Treatment of Chronic Hepatitis C
|
Phase 2/Phase 3 | |
Completed |
NCT00987337 -
Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects
|
Phase 2 | |
Completed |
NCT00929786 -
Anti-tuberculosis (TB) Drug Levels and Hepatotoxicity
|
N/A | |
Completed |
NCT00564642 -
Investigation of the Effect of N Acetylcysteine Against Anti-Tuberculosis Drugs Induced Liver Toxicity
|
N/A | |
Completed |
NCT00080236 -
Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation
|
Phase 2 | |
Recruiting |
NCT05719480 -
A Bidirectional Study in Exploring the Dynamic Changes of Plasma and Urine Metabolites of Liver Cancer
|
||
Suspended |
NCT04306939 -
Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study
|
||
Completed |
NCT03482388 -
Crowdsourcing to Promote HBV and HCV Testing in China
|
N/A |